OCGN (Ocugen Inc) רווח נקי למניה ב-12 החודשים האחרונים

Ocugen, Inc. (OCGN) minimizes risks by delegating development to external partners. This chart in the GURU.Markets terminal illustrates earnings per share over the last 12 months, where the -0.20 mark indicates the current yield level. Growth in these metrics is based on robotic selection of gene modifications and exclusive patents in ophthalmology, which grant the company the pricing power to independently determine the cost of its unique products.
OCGN (Ocugen, Inc.): פילוחים אנליטיים ודוחות לפי אינדיקטורים

Investors assess an asset's margin of safety through earnings per share, which offsets distortions found in quarterly reporting. For Ocugen, Inc. (OCGN), which is developing gene modification and upgrading laboratories, the 12-month change in EPS reflects the efficiency of R&D capital expenditures, determining the fundamental value of this biotechnology company.